Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;25(4):420-425.
doi: 10.1097/MOT.0000000000000771.

Recent advances in precision medicine for individualized immunosuppression

Shengyi Fu  1 , Ali Zarrinpar
Affiliations

Recent advances in precision medicine for individualized immunosuppression

Shengyi Fu et al. Curr Opin Organ Transplant. 2020 Aug.

Abstract

Purpose of review: The current tools to proactively guide and individualize immunosuppression in solid organ transplantation are limited. Despite continued improvements in posttransplant outcomes, the adverse effects of over-immunosuppression or under-immunosuppression are common. The present review is intended to highlight recent advances in individualized immunosuppression.

Recent findings: There has been a great focus on genomic information to predict drug dose requirements, specifically on single nucleotide polymorphisms of CYP3A5 and ABCB1. Furthermore, biomarker studies have developed ways to better predict clinical outcomes, such as graft rejection.

Summary: The integration of advanced computing tools, such as artificial neural networks and machine learning, with genome sequencing has led to intriguing findings on individual or group-specific dosing requirements. Rapid computing allows for processing of data and discovering otherwise undetected clinical patterns. Genetic polymorphisms of CYP3A5 and ABCB1 have yielded results to suggest varying dose requirements correlated with race and sex. Newly proposed biomarkers offer precise and noninvasive ways to monitor patient's status. Cell-free DNA quantitation is increasingly explored as an indicator of allograft injury and rejection, which can help avoid unneeded biopsies and more frequently monitor graft function.

PubMed Disclaimer

References

    1. Undre NA. Pharmacokinetics of tacrolimus‐based combination therapies. Nephrology Dialysis Transplantation. 2003. May 1;18(suppl_1):i12–5. - PubMed
    1. Zhu A, Leto A, Shaked A, Keating B: Immunologic Monitoring to Personalize Immunosuppression After Liver Transplant. Gastroenterol Clin North Am 2018, 47:281–296. - PubMed
    1. Leino AD, King EC, Jiang W, Vinks AA, Klawitter J, Christians U, Woodle ES, Alloway RR, Rohan JM. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: establishing baseline values. American Journal of Transplantation. 2019. May;19(5):1410–20. - PubMed

    2. This prospective study quantified the intra-patient variability of tacrolimus by assessing daily tacrolimus trough levels in an unchanged drug regimen with adherent patients.

    1. Gérard C, Stocco J, Hulin A, Blanchet B, Verstuyft C, Durand F, Conti F, Duvoux C, Tod M: Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. AAPS J 2014, 16:379–391. - PMC - PubMed
    1. Zhang X, Lin G, Tan L, Li J. Current progress of tacrolimus dosing in solid organ transplant recipients: pharmacogenetic considerations. Biomedicine & Pharmacotherapy. 2018. June 1;102:107–14. - PubMed

Publication types

MeSH terms

Substances